Searched for
DRL STOCK TARGET
Should you buy the dip? Strategist Anand James shares his weekly stock strategyMarket expert Anand James suggests caution following recent volatility. He notes the Nifty needs to break above 24,140 for a confirmed upsw...- DRL gears up for biosimilar push, consumer health growth post record FY25Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launc...
- Dr. Reddy’s Laboratories shares in focus on denial of workforce reductionDr. Reddy’s Laboratories shares: In a regulatory filing, the pharmaceutical giant addressed a Business Standard article dated April 13, whi...
- Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North ...
- Fortis among Kunal Shah's 3 stock buy ideas for the week“Nifty is showing signs of near-term bearishness as it forms a Double Top pattern on the daily chart, coupled with a bearish engulfing cand...
- Analysts fret about DRL's prospects, slash targetsThe Hyderabad-based pharma major was the biggest loser on the bourses with trading volume rising nearly 10 times after a majority of the an...
- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- Tata Motors enters BSE Sensex with effect from today, Dr Reddy’s Lab outAs per Trendlyne data, the highest target price for TaMo goes up to Rs 575, while the average target price estimate is Rs 495, an upside po...
- What CLSA says on Lupin; Morgan Stanley on DRL, Godrej ConsumerIn the case of DRL, Morgan Stanley said that the drug maker continued to deliver granular growth and that the growth trend should continue ...
- Buy Dr. Reddy's Laboratories, target price Rs 6400: Centrum BrokingDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 87734.71 Crore) operating i...
- How did India's Big Pharma fare in the December Quarter?Sun Pharma reported its highest-ever quarterly sales, and Cipla posted the highest-ever Ebitda margin in the company's recent history. Lupi...
- DRL plunges 5% post Q4 numbers; brokerages mixedDRL reported a 44 per cent year-on-year rise in profit at Rs 434.40 crore on Monday.
- Dr Reddy’s, feeling the pain now, looks better from long-term viewThe 'sell' recommendations on the stock more than doubled from 7 to 17 with leading brokerages downgrading the stock.
- DRL surges; company announces strategic alliance with BiocodexBiocodex has announced a change in partnership from October 1, giving complete rights to DRL for promotion and distribution of its products...
- Brokerages raise price target on Dr Reddy's to as high as Rs 2,720 on FDA nodBrokerages see the FDA approval to Dr Reddy’s Laboratories (DRL) for generic Vidaza as a positive for the company.
- Brokerage views on Dr Reddy’s, Jindal Steel, IT sector, Bajaj AutoRead on to know what brokerages have to say about select stocks that are expected be in action today:
- Brokerages maintain 'hold' on Dr Reddy's post resultsShares of Dr Reddy’s Laboratories (DRL) were down on profit booking after the company disappointed the street with its quarterly results ye...
- Why Dr Reddy's labs is going to report good resultsThe Hyderabad-based company with FY12 net sales Rs 9674 crore is expected to report good results to the cheer of its investors.
- Analyst's Pick: Dr Reddy's LaboratoriesCitigroup recommends 'Hold' rating on Dr Reddy’s Laboratories with a target price of Rs 547.
- DRL net dips 68% on price pressure, writedownDr Reddy’s Laboratories (DRL) suffered a 68% fall in Q4 net profit ended March 2008, after writing down the intangible value of the product...
Load More
